Lightnews — Scholar-powered news

JAMA Oncology @jamaoncology.com · 4d

Specific oral bacteria and fungi were risk factors for pancreatic cancer development, suggesting the potential use of oral microbiota as noninvasive biomarkers for identifying high-risk individuals.

ja.ma/4n9QpFm

Microbial community clusters. The figure displays a heatmap-style representation of microbial data across three clusters, categorized by oral pathogens, high/low-risk bacteria and fungi. Color intensity indicates relative abundance. Includes species names on the right.

1 1 4

JAMA Oncology @jamaoncology.com · 6d

In a pooled analysis of patients from 15 phase 3 trials, the risk of #coloncancer recurrence after surgery and adjuvant chemotherapy fell below 0.5% by six years, supporting this timepoint as a practical definition of cure to guide patient counseling and follow-up.

ja.ma/4764Q7y

Figure 1: Incidence Rate of Recurrence. Graph shows recurrence rate (%) over time since registration (years). Rate peaks at 1-2 years, declines until about 11 years, then rises slightly around 12-13 years. No. at risk decreases over time.

JAMA Oncology @jamaoncology.com · 6d

A phase 2 trial demonstrated an isotoxic improvement in #cancer control with prostate-specific membrane antigen positron emission tomography-guided intensification of salvage RT after radical prostatectomy.

ja.ma/48tWkkb

JAMA Oncology graphic shows an RCT study on PSMA-PET-Guided Intensification of Salvage Radiotherapy. It details the study's population (128 men), intervention(PSMAiSRT vs control), findings(improved survival), locations(2 centers in Canada), and outcomes.

1 1

JAMA Oncology @jamaoncology.com · 6d

A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. ja.ma/48AGALX

Kaplan-Meier plots comparing Ribociclib 400mg (RIB400) and 600mg (RIB600) for: A) Duration of Response (DOR), B) Time to Response (TTR), and C) Progression-Free Survival (PFS). Graphs show probability over time in months, with risk tables below.

JAMA Oncology @jamaoncology.com · 7d

Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer.

ja.ma/4pULwBQ

JAMA Oncology report: Ribociclib with endocrine therapy for ERBB2-negative early breast cancer. Study of 5101 patients. Graph shows invasive disease-free survival over 66 months. Ribociclib plus NSAI had fewer events than NSAI alone.

JAMA Oncology @jamaoncology.com · 8d

A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. ja.ma/42dA61P

JAMA Oncology @jamaoncology.com · 9d

Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer.

ja.ma/4nexdWS

JAMA Oncology @jamaoncology.com · 10d

More young people are now being diagnosed with lung cancer than in the past.

This JAMA Oncology Patient Page describes causes, types, and symptoms of lung cancer in people younger than 50 years and how it can be treated.

ja.ma/3Ksu86Z

Infographic about young-onset lung cancer, diagnosed before age 50. Symptoms listed include cough, breathing issues, chest pain, weight loss, and fatigue. Causes may include genetics, environment, & air pollution. Image features a woman and diagram of lungs with cancer.

JAMA Oncology @jamaoncology.com · 10d

A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. ja.ma/4ni9XqV

JAMA Oncology @jamaoncology.com · 11d

Head and neck cancer is the seventh most common cancer worldwide.

This Review provides an overview of EGFR-targeted therapies in HNSCC.

ja.ma/46EQOZn

Diagram titled "Cetuximab-Based Combination Regimens and Their Molecular Targets" shows T cell, NK cell, tumor cell interactions, and molecular pathways including EGFR, RAS, RAF, MEK, ERK, PI3K, AKT, mTOR involved in cell proliferation, growth, and survival.

2

JAMA Oncology @jamaoncology.com · 11d

A prediction model incorporating clonal hematopoiesis and other factors identified substantial heterogeneity in the cancer-preventive effect of low-dose aspirin among older adults.

ja.ma/3ILHWsR

Two graphs compare cumulative cancer incidence over time. Graph A (Placebo) shows treatment-favorable and unfavorable lines nearly overlapping. Graph B (Aspirin) shows the unfavorable line consistently higher than the favorable line.

JAMA Oncology @jamaoncology.com · 11d

Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer.

ja.ma/48vKYvJ

JAMA Oncology @jamaoncology.com · 13d

Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. ja.ma/3VwetpL

An editorial titled "Rethinking Ribociclib Dosage and Use in the Era of Patient-Centered Oncology—When Less Is More" by Rina Yadav, DO; Kathy D. Miller, MD. Article discusses hormone therapy and ribociclib dosage in breast cancer treatment.

JAMA Oncology @jamaoncology.com · 13d

Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer.

ja.ma/3VB5qnw

JAMA Oncology @jamaoncology.com · 13d

A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. ja.ma/3VzVJpi

JAMA Oncology @jamaoncology.com · 18d

Viewpoint: FDA analysis of primary clinical trial data frequently uncovers risks and flaws not apparent in published studies, highlighting the importance for clinicians to consider these regulatory insights in their treatment decisions.

ja.ma/4nxMv8M

JAMA Oncology viewpoint: "Improving Clinical Decisions Through Primary Trial Data Review—The Regulatory Lens" by Ning Jiang, Zhaoyi Yang, and Ning Li, published online September 18, 2025.

Reposted by JAMA Oncology

AMA @ama-assn.org · 19d

Key points from a recent @jamaoncology.com study on whether risk of pancreatic cancer could be linked to poor oral bacteria and fungi.

Can the oral microbiome help predict pancreatic cancer risk?

A JAMA Oncology cohort study of 122,000 people examines that question. Catch up with what else physicians are reading in JAMA Network journals.

spr.ly

1 8 13

JAMA Oncology @jamaoncology.com · 19d

Many elevated PSA levels normalize within a year, but consistently high values warrant direct diagnostic evaluation without repeated testing.

ja.ma/46xmBLD

A JAMA Oncology article titled "Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing" by Nicholas A. Pickersgill et al., published online September 18, 2025.

1

JAMA Oncology @jamaoncology.com · 20d

🔊 Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer.

Listen now: ja.ma/41Vzuh9

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD.

ja.ma

1 1

JAMA Oncology @jamaoncology.com · 20d

Specific oral bacteria and fungi were risk factors for pancreatic cancer development, suggesting the potential use of oral microbiota as noninvasive biomarkers for identifying high-risk individuals.

ja.ma/3K9xbAU

1 1 1

JAMA Oncology @jamaoncology.com · 20d

Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma.

ja.ma/486yf2H

Figure 2 shows clinical activity and end points. Graph A displays the best tumor change from baseline. Graph B displays confirmed responses. Graphs C and D display PFS and OS respectively with median values and confidence intervals labeled.

1

JAMA Oncology @jamaoncology.com · 21d

Viewpoint: Recognizing the heterogeneity of small cell lung cancer, efforts are underway to apply precision oncology through molecular subtyping and targeted therapies for tailored treatment. ja.ma/46xBWvU

A webpage excerpt from JAMA Oncology shows a viewpoint article titled "Shifting Toward Precision Oncology in SCLC Treatment" by Kostas A. Papavassiliou and Athanasios G. Papavassiliou, published online June 26, 2025.

JAMA Oncology @jamaoncology.com · 23d

Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. ja.ma/48f0BYg

Viewpoint article: "A Paradigm Shift Toward Population-Based MRI-Targeted Prostate Cancer Screening" by Ivo G. Schoots, MD, PhD; Anwar R. Padhani, MD, PhD. Discusses MRI's role in prostate cancer screening and its benefits.

JAMA Oncology @jamaoncology.com · 25d

Following trastuzumab deruxtecan approval, HER2 IHC 3+ testing across 65,000 solid tumors demonstrates varied prevalence. ja.ma/3JoJOb0

JAMA Oncology @jamaoncology.com · 25d

Following trastuzumab deruxtecan approval, HER2 IHC 3+ testing across 65,000 solid tumors demonstrates varied prevalence. ja.ma/3KkXRi7

Bar graph comparing HER2 positivity rates by tumor type using biopsy vs. resection. Bladder and uterine serous carcinoma show high positivity. Source: IHC 3+ data. Resection is generally lower than biopsy.